Formulation and Characterization of Nanoemulsion Intranasal Adjuvants: Effects of Surfactant Composition on Mucoadhesion and Immunogenicity-Reference-Cited by-同舟云学术

Formulation and Characterization of Nanoemulsion Intranasal Adjuvants: Effects of Surfactant Composition on Mucoadhesion and Immunogenicity

Published:2013-12-13 Issue:2 Volume:11 Page:531-544
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Wong Pamela T.¹,Wang Su He¹,Ciotti Susan²,Makidon Paul E.¹,Smith Douglas M.¹,Fan Yongyi¹,Schuler Charles F.¹,Baker James R.¹²

Affiliation:

1. Michigan Nanotechnology Institute for Medicine and Biological Sciences and Department of Internal Medicine, University of Michigan Medical School, 1150 W. Medical Center Dr., Ann Arbor, Michigan 48109, United States

2. NanoBio Corporation, 2311 Green Road, Suite A, Ann Arbor, Michigan 48105, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/mp4005029

Reference40 articles.

1. Nasal vaccines

2. Mucosal adjuvants

3. Mucosal immunity and vaccines

4. The role of adjuvants in the development of mucosal vaccines

5. Mucosal vaccines: the promise and the challenge

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in in vitro models simulating the female genital tract toward more effective intravaginal therapeutic delivery;Expert Opinion on Drug Delivery;2024-07-02

2. W/O/W Microemulsions for Nasal Delivery of Hydrophilic Compounds: A Preliminary Study;Journal of Pharmaceutical Sciences;2024-06

3. Enhanced mucosal B- and T-cell responses against SARS-CoV-2 after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant;2024-03-29

4. Nanoemulsions: Summary of a Decade of Research and Recent Advances;Nanomedicine;2024-01-31

5. A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation;Cancer Gene Therapy;2024-01-04